Current situation of Bristol-Myers Squibb Stock
This pharmaceutical firm had to bear with the wrath of the coronavirus pandemic. The main reason for this downfall was the locking down of the world for a specific amount of time to control the spread of the coronavirus. The virus, however, spread very quickly and affected a massive number of lives. The various sectors which had to suffer back then are now trying to recover from the losses they suffered at that time. Bristol-Myers Squibb underwent losses because access to the hospitals and clinics was limited. Not all the patients could go to the hospitals because of the lockdowns or curfews and most importantly, the fear of the spread of the virus kept people away from the hospitals for some amount of time. However, the year 2020 is not enough for the description of the performance of this firm because the company has had an overall better performance during the past times. It is also expected that the company will bounce back and perform well again in this year as well as the upcoming years. Bristol-Myers Squibb Co. (NYSE: BMY) 52 Week Range: $45.76 - $67.80 Average Volume: 10,731,482 Market Capital: $145.889B Forward Dividend and Yield: 96 (3.05%) Another plus point about the company is that its dividend has consistently increased for 11 years straight and there are no chances that it will stoop down so the investors can rely on the company for that matter. Moreover, the stocks are moderately priced and profitable giving so there is little…
